Novavax, Inc.

-5.04 (-8.63%)
: $54.13 +0.74 (+1.39%)

Novavax Announces Participation In Two Booster Studies Using Its Covid-19 Vaccine

Published: 03/25/2022 12:59 GMT
Novavax, Inc. (NVAX) - Novavax Announces Participation in Two Booster Studies Using Its Covid-19 Vaccine.
Novavax - Trial Will Evaluate Heterologous Booster Regimens, Including Nvx-cov2373, After Primary Series With Current FDA Approved/eua-vaccines.
Novavax Inc - Participants Will Be Followed for 12 Months, With Topline Results Expected Later This Year and Full Results Expected in 2023.
Novavax - Study is Enrolling About 1,130 Healthy Individuals Aged 18 Years Or Older, About 180 of Whom to Get Nvx-cov2373 As a Heterologous Booster.
Novavax Inc - Participating in an Ongoing Phase 1/2 Trial Sponsored by National Institute of Allergy and Infectious Diseases.
Novavax Inc - Also Being Evaluated in an Observer-blinded Phase 3 Study in United Arab Emirates.
Novavax Inc - Participants for Uae Trial Will Be Followed for Six Months, With Full Results Expected During Q4 of 2022.
Novavax Inc - Uae Study is Enrolling Approximately 1,000 Participants Aged 18 Years Or Older at Two Centers in Abu Dhabi.